Central Serous Chorioretinopathy Developed Following Covid-19 Vaccine

dc.contributor.authorCoskun, M.
dc.date.accessioned2024-09-29T16:16:14Z
dc.date.available2024-09-29T16:16:14Z
dc.date.issued2023
dc.departmentKarabük Üniversitesien_US
dc.description.abstractA 40-year-old male patient, an office worker, is a hospital staff. He applied with the complaint of sudden onset of blurred vision in the right eye. He stated that he had the first dose of inactivated covid vaccine (sinovac) 4 days ago in his story. In his examination, his vision was 0.5 in the right eye, 1.0 in the left eye, and his intraocular pressure was in both eyes. It was at the level of 15 mmHg. Biomicroscopically, the anterior segment looked natural. CSC was diagnosed in the FFA and OCT examinations.Treatment with oral acetazolamide (2x250 mg), topical nepafanac (4x1) was started. On the 13th day of the treatment, there was insufficient improvement in clinical findings, and oral acetazolamide was used. The dose was reduced (2x125 mg), oral epleronone (50 mg) was added. On the 70th day of the treatment, the vision in the right eye increased to full level in the control examination and it was observed that the retina returned to its normal appearance in the OCT examination. © 2023 Gazi Eye Foundation. All rights reserved.en_US
dc.identifier.doi10.37845/ret.vit.2023.32.12
dc.identifier.endpage73en_US
dc.identifier.issn1300-1256
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85160080827en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage70en_US
dc.identifier.trdizinid1184447en_US
dc.identifier.urihttps://doi.org/10.37845/ret.vit.2023.32.12
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1184447
dc.identifier.urihttps://hdl.handle.net/20.500.14619/8949
dc.identifier.volume32en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherGazi Eye Foundationen_US
dc.relation.ispartofRetina-Vitreusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcorioretinopathy, coviden_US
dc.titleCentral Serous Chorioretinopathy Developed Following Covid-19 Vaccineen_US
dc.typeArticleen_US

Dosyalar